The latest international news, analysis and features on the HIV epidemic from AVERT. Share your views and expertise with your peers in the comments box below the articles.
A delayed tendering process for antiretroviral drugs by the Indian National AIDS Control Organisation (NACO) meant that 150,000 people living with HIV (PLHIV) in India were at risk of being without antiretroviral treatment (ART) for October. This is a continuation of the drugs crisis AVERT reported on last month, which saw NACO having issues procuring drugs. Recently, a coalition of Indian pharmaceutical companies, the World Health Organisation (WHO), Medicine San Frontier (MSF) and others have come together to fill the gap of missing drugs.
Two thirds of children from low and middle-income countries are presented for HIV treatment with severe immunodeficiency, a new study has revealed. Current WHO guidelines recommend that treatment is available for all HIV positive children under the age of five, regardless of their CD4 count, in order to curb the epidemic among younger generations.
HIV drug shortages in India over the past few months have meant that many people living with HIV (PLHIV) are unable to access antiretroviral treatment (ART) through government run distribution centres. Thousands of PLHIV rely on the free ART provided by India’s National AIDS Control Organization (NACO), however they are facing drug shortfalls that are largely blamed on supply bottlenecks, late payments to pharmaceutical companies and Indian manufacturers boycotting the process.